Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi : Signs Agreement with Principia Biopharma for MS Drug Candidate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/09/2017 | 01:15pm CET

By Sonia Amaral Rohter

Sanofi SA (SAN.FR) on Thursday said that it has signed a license agreement with Principia Biopharma Inc. to develop an experimental oral treatment for multiple sclerosis, or MS, as part of its efforts to expand its MS franchise.

Under the terms of the deal, Sanofi will be granted an exclusive, worldwide license to develop and commercialize the drug, which is currently under clinical development. Sanofi will make an upfront payment of $40 million to Principia, and Principia will receive future milestone payments of up to $765 million as well as royalties on product sales.

According to the company, the drug candidate, referred to as PRN2246, shows promise in treating MS, a chronic inflammatory disorder of the central nervous system that affects over 2.5 million people worldwide. Principia has recently initiated a phase 1 trial of PRN2246 in healthy volunteers, according to the release.

Sanofi already has two MS medicines on the market, Aubagio and Lemtrada, as well as an in-house research and development program to address MS and other neurological diseases.

"Our agreement with Principia is an example of Sanofi's strategic commitment to build our drug discovery and development pipeline in MS and neurological diseases," says Rita Balice-Gordon, global head of the company's MS/neuroscience therapeutic research area. "Complementing our own internal R&D expertise, external relationships like this may accelerate delivery of new treatments to patients living with these serious diseases."

The transaction, which is subject to customary regulatory approvals, is expected to close in the fourth quarter.

Write to Sonia Amaral Rohter at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
11/18 SANOFI : Uptake Strategies and Sanofi win capability development prize at PMEA
11/16 SANOFI : UGA, Sanofi Pasteur develop new broadly protective vaccines for H3N2 in..
11/16 SANOFI : brings innovative medication to Saudi Arabia
11/15 SANOFI : UGA Research Team Explores Impact of Age on Response to Influenza Vacci..
11/15 DR REDDY LABORATORIES : Launches clofarabine generic injection in us
11/14 SANOFI : Principia agree to develop multiple sclerosis drug candidate
11/14 Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Prov..
11/14 IQVIA : Mylan Launches Generic Clolar for Injection
11/14 SANOFI : Experts clarify myths around diabetes
11/13 SANOFI : Body’s inability to manage glucose cause of diabetes not sugar, f..
More news
News from SeekingAlpha
11/16 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
11/15 SANOFI Q3 2017 : Weak Signals
11/15 Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q3 2017 Update
11/14 HEALTHCARE DOGFIGHT : GlaxoSmithKline Regains Top By Gains In November As O&M & ..
11/13 Sanofi Wants To Make A Major Footprint In The Multiple Sclerosis Space
Financials (€)
Sales 2017 35 939 M
EBIT 2017 9 366 M
Net income 2017 7 904 M
Debt 2017 4 659 M
Yield 2017 4,02%
P/E ratio 2017 12,15
P/E ratio 2018 16,16
EV / Sales 2017 2,78x
EV / Sales 2018 2,72x
Capitalization 95 278 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 85,3 €
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-1.91%112 309
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550